Literature DB >> 15968103

The SCID-hu myeloma model.

Joshua Epstein1, Shmuel Yaccoby.   

Abstract

The severe combined immune deficient human (SCID-hu) myeloma model is the only available model in which primary myeloma cells grow in vivo in a human bone marrow micro environment. A SCID mouse receives an implanted human fetal bone into which myeloma cells are directly injected. Through interaction with the human bone marrow microenvironment, the myeloma cells induce typical myeloma manifestations in the SCID host, such as the appearance of M protein in the serum, and changes in the implanted human bone, which often result in osteolysis of the human bone. The model provides the only platform for in vivo investigation of the biology and therapy of primary human myeloma in a human microenvironment. This chapter describes in detail all the steps necessary to establish this model and evaluate its success.

Entities:  

Mesh:

Year:  2005        PMID: 15968103     DOI: 10.1385/1-59259-916-8:183

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  8 in total

1.  β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome-aggresome-autophagosome-lysosome pathway.

Authors:  K Sukhdeo; M Mani; T Hideshima; K Takada; V Pena-Cruz; G Mendez; S Ito; K C Anderson; D R Carrasco
Journal:  Leukemia       Date:  2011-11-04       Impact factor: 11.528

2.  Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.

Authors:  W Grady Gunn; Ulf Krause; Narae Lee; Carl A Gregory
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 3.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

4.  Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

Authors:  Frits van Rhee; Susann M Szmania; Myles Dillon; Anne M van Abbema; Xin Li; Mary K Stone; Tarun K Garg; JuMei Shi; Amberly M Moreno-Bost; Rui Yun; Balaji Balasa; Bishwa Ganguly; Debra Chao; Audie G Rice; Fenghuang Zhan; John D Shaughnessy; Bart Barlogie; Shmuel Yaccoby; Daniel E H Afar
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

5.  Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4.

Authors:  Leonardo Mirandola; Yuefei Yu; Marjorie R Jenkins; Raffaella Chiaramonte; Everardo Cobos; Constance M John; Maurizio Chiriva-Internati
Journal:  BMC Cancer       Date:  2011-09-16       Impact factor: 4.430

Review 6.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

7.  NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.

Authors:  Michelle A Lawson; Julia M Paton-Hough; Holly R Evans; Rebecca E Walker; William Harris; Dharshi Ratnabalan; John A Snowden; Andrew D Chantry
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

8.  Bone-targeted agents in multiple myeloma.

Authors:  Hiroko Nishida
Journal:  Hematol Rep       Date:  2018-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.